Maju Mathews

Learn More
36 INTRODUCTION Antipsychotic drugs are the mainstay of treatment of schizophrenia and other psychotic disorders. The therapeutic efficacy of these drugs is well established. However, these drugs are associated with a wide range of side effects, including a variety of movement disorders. The newer antipsychotics have a lower propensity to cause acute(More)
Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine its effects on sexual function. The primary study was a double-blind, randomized, controlled trial comparing(More)
Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A partial agonist approved for major depressive disorder (MDD) treatment in adults. This was a 10-week, multicenter, double-blind, placebo-controlled and active-controlled, fixed-dose trial (NCT01473381). Adult patients with MDD (Diagnostic and Statistical Manual of Mental Disorders, 4th ed.,(More)
The aim of this study was to evaluate the efficacy of vilazodone using different definitions of remission. Post-hoc analyses were carried out using data from an 8-week, multicenter, randomized, double-blind, placebo-controlled trial of vilazodone 40 mg/day in adults with major depressive disorder (NCT01473394). The primary efficacy endpoint was a mean(More)
Malingering is the deliberate production of false, (or gross exaggeration of), physical or psychologic symptoms for a known external reward. It is not considered a form of mental illness or psychopathology, although it can occur in the context of other mental illnesses. Even though it is easy to define, clinicians still find making the diagnosis very(More)
The aim of this study is to evaluate the effects of vilazodone on sexual functioning in healthy, sexually active adults and assess the impact of medication nonadherence in this type of trial. Participants were randomized to vilazodone (20 or 40 mg/day), paroxetine (20 mg/day), or placebo for 5 weeks of double-blind treatment. The primary endpoint was change(More)